2021
July Newsletter
News

bms_logo.png
BMS and MBC BioLabs Announce 2021 Golden Ticket Competition
Bristol Myers Squibb will award Golden Tickets to two innovative biotechs pursuing research in the fields of oncology, hematology, immunoscience, cardiovascular disease, neuroscience or fibrotic diseases. A Golden Ticket provides the awardee with a sponsored lab bench and access to millions of dollars worth of research equipment for one year. Click below to complete the application.
jupiter_therapiutics_logo.png
ONO Announces Winner of 2021 Golden Ticket Competition
ONO and MBC BioLabs are delighted to announce Jupiter Therapeutics, Inc. as the winner of their "Golden Ticket Competition". The award enables entrepreneurial scientists and emerging biotechnology start-ups accelerate early drug discovery and innovation for the potential future benefit of patients worldwide.
CLICK TO READ MORE
kit_logo.png?2
Ro Acquires Kit Right Out of Our Labs!
Kit partners with health insurers, clinical trials, self-insured employers and telehealth platforms to create customizable at-home diagnostic tests. It essentially serves as a white-label solution for physicians, giving them an ordering portal for them to request and tweak the tests that can eventually be delivered to consumers. The company's in-network approach comes as a contrast to Ro's vision of direct-to-consumer healthcare, so it will be key to see how Kit customers are impacted by the transaction and if You can bring down prices to hit consumer-friendly benchmarks.
CLICK TO READ MORE
New Companies

gpcr_logo.png?1
GPCR Therapeutics
GPCR Therapeutics USA is a newly incorporated Biotechnology company in the Bay area originatinating from GPCR Therapeutics Inc., Korea. Our mission is to discover and develop innovative therapeutics targeting cancer based on the novel science of G protein coupled receptors (GPCR) heteromers. The most advanced clinical candidate, Burixafor, is planned to initiate a clinical trial in the US next year, focusing on our CXCR4 heteromer hypothesis. Additionally, we will be utilizing our technologies to identify key GPCR heteromers as therapeutics targets in Oncology. Dr. Pina Cardarelli will be heading up the team of talented researchers that will be expanding in the coming years.
CLICK TO LEARN MORE
vcreate_logo.png
Vcreate
Vcreate is building a platform to accelerate the development of T-cell receptor (TCR) based therapies. TCR based therapies offer a promising alternative to CAR-T for solid tumors and other diseases, but identifying clinically relevant TCRs usually takes years and costs millions of dollars. We aim to dramatically reduce this development time -- from years to weeks -- through our novel TCR screening assays and machine learning models.
CLICK TO LEARN MORE
thelium_logo.png
Thelium Therapeutics
Thelium Therapeutics is a preclinical stage company developing first-in-class, non-immunosuppressive small molecule therapies to restore epithelial barrier function in inflammatory diseases. We employ novel precision targeting approaches for barrier restoration that yields disease attenuation by taming immunological activation.
CLICK TO LEARN MORE
MBC BioLabs, Enabling Awesome
bottom border